Timothy Mayer Ph.D. serves as Chief Operating Officer of the Company. He previously served as our Senior Vice President, Corporate Development from December 2018 to October 2019 and our Vice President, Business Development from February 2016 to December 2018. Prior to joining NextCure, Dr. Mayer held several positions at MacroGenics, Inc., a biopharmaceutical company focused on the treatment of cancer, from 2004 to February 2016, including Senior Director, Intellectual Property from 2009 to February 2016. Prior to that, Dr. Mayer worked on biotechnology and pharmaceutical patent matters as a Technical Specialist at Banner & Witcoff, Ltd., an intellectual property law firm, from 2000 to 2004. Dr. Mayer received a B.S. in microbiology and a B.S. in biochemistry from California Polytechnic State University and a Ph.D. in microbiology and immunology from the Pennsylvania State University College of Medicine.
As the Chief Operating Officer of Nextcure Inc, the total compensation of Timothy Mayer at Nextcure Inc is $248,420. There are 9 executives at Nextcure Inc getting paid more, with Steven Cobourn having the highest compensation of $993,341.
Timothy Mayer is 55, he's been the Chief Operating Officer of Nextcure Inc since 2019. There are 17 older and 4 younger executives at Nextcure Inc. The oldest executive at Nextcure Inc is David Kabakoff, 72, who is the Independent Chairman of the Board.
Timothy's mailing address filed with the SEC is C/O NEXTCURE, INC., 9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE, MD, 20705.
Over the last 5 years, insiders at Nextcure Inc have traded over $0 worth of Nextcure Inc stock and bought 1,475,000 units worth $25,387,500 . The most active insiders traders include Advisors Llc Orbi Med Capit..., Chau Quang Khuong und Timothy M Shannon. On average, Nextcure Inc executives and independent directors trade stock every 48 days with the average trade being worth of $233,653. The most recent stock trade was executed by Kevin N. Heller on 14 July 2020, trading 27,229 units of NXTC stock currently worth $48,195.
nextcure, inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. its lead product candidate is nc318, which is in phase 2 clinical trials for the treatment of advanced or metastatic solid tumors. the company is also developing nc410, is a novel immunomedicine designed to block immune suppression mediated by an immune modulator called leukocyte-associated immunoglobulin-like receptor 1. its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules that targets a novel member of the b7-family of immunomodulatory proteins; and an antibody in preclinical development targeting an immune modulator that is expressed in inflamed tissue and the tumor microenvironment in various tumor types. nextcure, inc. has a license agreement with yale university; and a research and development col
Nextcure Inc executives and other stock owners filed with the SEC include: